Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Researchat Helix BioPharma Corp., a developer of novel cancer therapeutics,will be presenting a scientific poster at the Fourth InternationalConference on Tumor Microenvironment, which runs from March 6th to10th in Florence, Italy. The conference, hosted by the...

Replidyne Phase II Pediatric Trial Meets Primary Objective

LOUISVILLE, Colo., March 06, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. announced today that it has completed its Phase IIclinical trial using faropenem medoxomil (faropenem) in pediatricpatients with acute otitis media (AOM), a common infection of themiddle ear. Initial analyses of the study results show that it metits primary objective to show that faropenem was effective ineradicatin...

DVT Awareness Survey Findings: Heart and Respiratory Patients

WASHINGTON, March 06, 2007 /PRNewswire/ -- Up to two millionAmericans are affected each year by DVT, with up to 600,000hospitalized. Its primary complication, pulmonary embolism (PE),claims up to 300,000 lives annually -- more than breast cancer andAIDS combined. People who suffer from cardiovascular disease may beat increased risk for DVT, because these factors also heighten thelikelihood...

Pozen Announces Positive Outcome for PA 325

Chapel Hill, N.C., March 6, 2007-Pozen Inc. (NASDAQ: POZN),today announced top-line results of its "Safer Aspirin" PA 325proof-of-concept study conducted during the fourth quarter of 2006.PA 325 is a patented formulation of 325mg of aspirin surrounded bya 20mg coating of an immediate release formulation of a proton pumpinhibitor. The PA 325, 28 day study, involved two groups of 40 subject...

Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings

CAMBRIDGE, Mass., March 06, 2007 /PRNewswire-FirstCall/ --Advanced Magnetics today announced that data from three completedPhase III multi- center clinical studies of ferumoxytol as anintravenous iron replacement therapeutic will be presented duringthe National Kidney Foundation (NKF) 2007 Spring Clinical Meetingstaking place April 10th through 14th in Orlando, Florida. Twoposters containi...

POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar 6, 2007 - POZEN Inc.(NASDAQ: POZN), today announced top-line results of its "SaferAspirin" PA 325 proof-of-concept study conducted during the fourthquarter of 2006. PA 325 is a patented formulation of 325mg ofaspirin surrounded by a 20mg coating of an immediate releaseformulation of a proton pump inhibitor. The PA 325, 28 day study, involved two group...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

- 78 Percent of Patients Showed Complete Response or Reduction ofLesion Size by More than Fifty Percent - SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - NventaBiopharmaceuticals Corporation today announced the presentation ofpositive results from a clinical trial examining the safety andefficacy of pilot process HspE7, an investigational therapeuticvaccine for human papillomavirus (...

AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy

VIENNA, Austria and CHAPEL HILL, N.C., US, March 06, 2007/PRNewswire/ -- AOP Orphan Pharmaceuticals AG ("AOP Orphan") andLantibio, Inc. ("Lantibio") today announced positive final resultsfrom their placebo controlled, double-blinded Phase II clinicalstudy of Moli1901, an experimental compound to treat cysticfibrosis ("CF"). Moli1901 is being developed by AOP Orphan inEurope under a licensi...

Advanced Cell Technology's Ability to Rescue Vision in Blind Rats Noted in Scientific American

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 5, 2007 - Advanced CellTechnology, Inc.'s (OTCBB: ACTC) ability to rescue vision in blindrats was noted in Scientific American's March 2007 issue as thelead story of its News Scan section. The full text of the article,which notes Advanced Cell's ability to "coax embryonic stem cellsto turn into transplantable retinal pigment epithelial (RPE)tissue," is...

Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters atthe Annual Meeting of the American Academy of Allergy, Asthma, andImmunology from February 23 - 27, 2007 in San Diego, CA. Theposters discussed findings from a survey of 202 otolaryngologists(ENTs) and allergists in the U.S., U.K., France, and Germany on theburden of chroni...
[next]
(Date:10/11/2019)... ... October 11, 2019 , ... A Topping Out event was hosted today at ... contractors Adolfson & Peterson Construction. The event celebrated reaching the final height of the ... Dallas. The first of its kind in Texas, STA’s facility will be home to ...
(Date:10/10/2019)... Calif. (PRWEB) , ... October 10, 2019 , ... Caring.com, ... Living Report on the Best and Worst Places for Seniors to Live. All 50 ... community engagement, transportation, quality of life and workforce development. , According to the ...
(Date:10/8/2019)... VANCOUVER, British Columbia (PRWEB) , ... October 08, 2019 , ... ... about the current and future state of aging and wellness in the nation? That ... International Council on Active Aging Conference, Leadership Summit and Expo. The event will take ...
(Date:10/8/2019)... CA (PRWEB) , ... October 08, 2019 , ... Dr. ... gum disease in San Jose, CA experience relief from this common and treatable condition. ... in order to save adults from living with uncomfortable symptoms, including tender and bleeding ...
(Date:10/8/2019)... ... October 08, 2019 , ... As a ... Meiqing Shi, associate professor with the University of Maryland Department of Veterinary Medicine, ... in Nature Communications, Shi and his lab have discovered a new pathway by ...
Breaking Medicine News(10 mins):
... report , , TUESDAY, Dec. 18 (HealthDay News) -- Advances ... kidney, head and neck and lung cancers are among ... American Society of Clinical Oncology says in a new ... improving the lives of many cancer patients, flat federal ...
... Hemodynamic and Implantability Characteristics, MINNEAPOLIS, Dec. ... ), manufacturer and marketer of state-of-the-art cardiac,surgery ... and Drug,Administration (FDA) approval for the ATS ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), The ATS AP360 ...
... first Phase II clinical trial, MELBOURNE, Australia, Dec. ... to proceed with a Phase II clinical,study assessing its ... Patient enrolment will soon commence., This Phase II ... clinical,studies planned for the anti-cancer vascular-disrupting agent CYT997 and,will ...
... Dec. 17 CBS News will be running the,story ... Colorado Hospital,-- ,SAFER CHEMOTHERAPY, THANKS TO A NEW ROBOT ... FRC-Path, Nancy Stolpman, PharmD, PhD, and,a patient were interviewed ... which automates chemotherapy compounding for syringes and IV bags.,University ...
... Dec. 17 Whether enjoying a meal at,home, at ... be health conscious,but don,t want to sacrifice great taste ... eat right. The leader in the frozen sandwich category ... enjoy the goodness,of whole grains in every bite with ...
... WASHINGTON, Dec. 17 AARP CEO William Novelli,made ... health care,reform bill (ABX1 1) by the California ... Pro Tem Perata and,other members of the California ... such impressive progress toward comprehensive,health care reform., ...
Cached Medicine News:
... models cover the range from 2ul to 5000ul. ... Volume lock design prevents inadvertent volume change. ... Whole pipette is autoclavable at 121C(250F). ... polypropylene. Suitable for one-handed operation. Auto ...
... Pipetman Ultra is a fully adjustable, ... display. It is the latest member of ... same characteristics: robustness, accuracy, and precision. We ... on feedback from our customers. Eight models ...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
... from 2ul to 5000ul. Fills and empties ... inadvertent volume change. Novel hand grip shape ... autoclavable at 121C(250F). To prevent corrosion the ... one-handed operation. Auto or Normal trigger mode. ...
Medicine Products:
(Date:10/15/2019)... Calif. (PRWEB) , ... October 14, 2019 , ... An ... to the mounting evidence suggesting a correlation between tooth loss and heart disease. The ... teeth had a 28 percent chance of also having heart-related problems, compared to just ...
(Date:10/11/2019)... ... October 11, 2019 , ... Based on data for the ... percent increase in deceased organ donors over 2018. Through August 31, 7,786 deceased donors ... (OPTN) national database . At this pace, the Association of Organ Procurement Organizations ...
(Date:10/10/2019)... , ... October 10, 2019 , ... ... Championships , 2019 ITTF Parkinson World Table Tennis Championships, October 11th – 13th, ... music and perform in public. So, he sought to find a way to ...
Breaking Medicine Technology:
... annual meeting recombinant factor, VIIa-albumin fusion protein seen ... treatment option for hemophilia patients with inhibitors, ... of a pre-clinical study that show for the first time ... albumin, prolonging the,half- life of this therapeutic protein while retaining ...
... Vanderbilt Medical Center is,seeking local residents with ... a national clinical study evaluating an investigational,device, the ... Tennessee., The TANTALUS System is an implantable ... a person eats. The primary objective of the,randomized, ...
Cached Medicine Technology: